[526] Lymphovascular Markers in Melanoma Sentinel Lymph Nodes
Stewart G Neill, Grant W Carlson, Andrew J Page, Jason Wang, Cynthia Cohen. Emory University School of Medicine, Atlanta, GA
Background: Cutaneous malignant melanomas principally metastasize to lymph nodes, and sentinel lymph node (SLN) sampling has become a critical facet of melanoma prognosis and treatment. Evidence has shown that melanomas trigger lymphangiogenesis at the tumor-stromal junction and that this process is correlated with SLN metastasis. Further, there is evidence that melanomas may produce premetastatic niches in SLNs through a similar process of influencing lymphangiogenesis. SLNs excised in the treatment of melanomas were retrospectively stained for lymphovascular immunohistochemical markers (CD31, CD34, D2-40) to identify changes in intranodal vascular density and correlate those changes with clinical outcomes.
Design: 65 melanomas with SLN biopsy, clinical follow-up, and adequate paraffin-embedded nodal tissue were studied. Immunohistochemistry for CD31, CD34, and D2-40 was performed. Stained slides were analyzed for microvessel density (MVD) based upon the manual quantitation of vessels within three 20x high-powered fields over “hot spots”. Automated quantitation of staining density and intensity was performed using a Dako ACIS III scanner. Mean MVDs, mean staining percentages (% stain), and mean staining intensities were compared.
Results: 65 melanoma patients included 8 with negative SLNs and recurrence, 26 with negative SLNs and no recurrence, and 31 positive nodes with and without recurrence.
| CD31 | D2-40 | ||||||
| Number | Mean MVD | % Stain | Intensity | Mean MVD | % Stain | Intensity | |
| Negative with recurrence | 8 | 78.5* | 50.1 | 101.4* | 9.1 | 22.5* | 69.4* |
| Negative without recurrence | 26 | 117.5* | 44.2 | 84.2* | 6.2 | 13.1* | 71.3* |
| Positive | 31 | 93.7* | 37.4 | 89.4* | 7.2 | 7.1* | 63.8* |